Evaluation of Statin Indication and Dose Intensification Among Type 2 Diabetic Patients at a Tertiary Hospital

References

• Farmer JA. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. Curr Diabetes Rep. 2008;8(1):71–77. doi:10.1007/s11892-008-0013-2
   PubMed Web of Science ®Google Scholar
• De Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs. 2012;72(18):2365–2373. doi:10.2165/11638240-000000000-00000
   PubMed Web of Science ®Google Scholar
• Kurihara O, Thondapu V, Kim HO, et al. Comparison of vascular response to statin therapy in patients with versus without diabetes mellitus. Am j Cardiol. 2019;123(10):1559–1564. doi:10.1016/j.amjcard.2019.02.020
   PubMed Web of Science ®Google Scholar
• Almeida SO, Budoff M. Effect of statins on atherosclerotic plaque. Trend Cardiovasc Med. 2019;29(8):451–455. doi:10.1016/j.tcm.2019.01.001
   PubMed Web of Science ®Google Scholar
• Bavishi A, Howard T, Kim JP, et al. Treatment gap in primary prevention patients presenting with acute coronary syndrome. Am J Cardiol. 2019;123(3):368–374. doi:10.1016/j.amjcard.2018.10.034
   PubMed Web of Science ®Google Scholar
• Care I Standards of medical care in diabetes—2018 Abridged for primary care providers; 2018.
   Google Scholar
• Ofori SN, Odia OJ. Risk assessment in the prevention of cardiovascular disease in low-resource settings. Indian Heart J. 2016;68(3):391–398. doi:10.1016/j.ihj.2015.07.004
   PubMedGoogle Scholar
• Alkhail BA, Iftikhar R, Al Shaikh A. Use of aspirin and statin as primary prevention for cardiovascular diseases. Pak J Med Sci. 2016;32(6):1336. doi:10.12669/pjms.326.10615
   PubMed Web of Science ®Google Scholar
• de Vries FM, Voorham J, Hak E, Denig P. Prescribing patterns, adherence and LDL‐cholesterol response of type 2 diabetes patients initiating statin on low‐dose versus standard‐dose treatment: a descriptive study. Int J Clin Pract. 2016;70(6):482–492. doi:10.1111/ijcp.12806
   PubMed Web of Science ®Google Scholar
• Danese MD, Gleeson M, Kutikova L, et al. Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ open. 2017;7(5):e013851. doi:10.1136/bmjopen-2016-013851
   PubMed Web of Science ®Google Scholar
• Demoz GT, Wahdey S, Kasahun GG, et al. Prescribing pattern of statins for primary prevention of cardiovascular diseases in patients with type 2 diabetes: insights from Ethiopia. BMC Res Notes. 2019;12(1):1–7. doi:10.1186/s13104-019-4423-9
   PubMedGoogle Scholar
• Melaku T, Solomon Y, Chelkeba L. Statin utilization patterns among Type 2 diabetes mellitus patients with high cardiovascular disease risks in Ethiopia. J Pharm Care. 2018;3:44–51.
   Google Scholar
• Tolla MT, Norheim OF, Memirie ST, et al. Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis. Cost Eff Resour Allocation. 2016;14(1):1–14. doi:10.1186/s12962-016-0059-y
   PubMedGoogle Scholar
• Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. The role of statins in the treatment of type 2 diabetes mellitus: an update. Curr Pharm Des. 2014;20(22):3665–3674. doi:10.2174/13816128113196660673
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168–3209. doi:10.1016/j.jacc.2018.11.002
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. Circulation. 2019;139(25):e1162–e1177. doi:10.1161/CIR.0000000000000638
   PubMed Web of Science ®Google Scholar
• Zhou S, Nie S, Xin X. # 4326 Statin initiation and risk of incident kidney disease in patients with diabetes. Nephrol Dial Transplant. 2023;38(Supplement_1):gfad063c_4326. doi:10.1093/ndt/gfad063c_4326
   PubMedGoogle Scholar
• Mwita JC, Godman B, Esterhuizen TM. Statin prescription among patients with type 2 diabetes in Botswana: findings and implications. BMC Endocr Disord. 2020;20(1):1–9. doi:10.1186/s12902-020-0516-7
   PubMed Web of Science ®Google Scholar
• Elnaem MH, Mohamed MHN, Huri HZ, Azarisman SM, Elkalmi RM. Statin therapy prescribing for patients with type 2 diabetes mellitus: a review of current evidence and challenges. J Pharm Bioallied Sci. 2017;9(2):80. doi:10.4103/jpbs.JPBS_30_17
   PubMedGoogle Scholar
• Lee VW, Ho IC, Chan WS, Tam KY, Lee KK. Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong. Am J Cardiovasc Drugs. 2008;8(3):199–205. doi:10.2165/00129784-200808030-00006
   PubMed Web of Science ®Google Scholar
• Sobngwi E, Ndour-Mbaye M, Boateng KA, et al. Type 2 diabetes control and complications in specialised diabetes care centres of six sub-Saharan African countries: the Diabcare Africa study. Diabetes Res Clin Pract. 2012;95(1):30–36. doi:10.1016/j.diabres.2011.10.018
   PubMed Web of Science ®Google Scholar
• Preiss D, Kristensen SL. The new pooled cohort equations risk calculator. Cana J Cardiol. 2015;31(5):613–619. doi:10.1016/j.cjca.2015.02.001
   PubMed Web of Science ®Google Scholar
• Topel ML, Shen J, Morris AA, et al. Comparisons of the Framingham and pooled cohort equation risk scores for detecting subclinical vascular disease in blacks versus whites. Am j Cardiol. 2018;121(5):564–569. doi:10.1016/j.amjcard.2017.11.031
   PubMed Web of Science ®Google Scholar
• Boateng D, Agyemang C, Beune E, et al. Cardiovascular disease risk prediction in sub-Saharan African populations—Comparative analysis of risk algorithms in the RODAM study. Int J Cardiol. 2018;254:310–315. doi:10.1016/j.ijcard.2017.11.082
   PubMed Web of Science ®Google Scholar
• Ashraf T, Mengal MN, Muhammad AS, et al. Ten years risk assessment of atherosclerotic cardiovascular disease using Astro-CHARM and pooled cohort equation in a south Asian sub-population. BMC Public Health. 2020;20(1):1–6. doi:10.1186/s12889-020-08472-4
   PubMed Web of Science ®Google Scholar
• Elnaem MH, Mohamed MHN, Huri HZ, Shah ASM. Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings. Ther Clin Risk Manage. 2019;15:137–145. doi:10.2147/TCRM.S182716
   PubMed Web of Science ®Google Scholar
• Shah AS, Dolan LM, Kimball TR, et al. Influence of duration of diabetes, glycemic control, and traditional cardiovascular risk factors on early atherosclerotic vascular changes in adolescents and young adults with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94(10):3740–3745. doi:10.1210/jc.2008-2039
   PubMed Web of Science ®Google Scholar
• Elkomos M, Jahromi R, Kelly MS. Pharmacist-led programs to increase statin prescribing: a narrative review of the literature. Pharmacy. 2022;10(1):13. doi:10.3390/pharmacy10010013
   Web of Science ®Google Scholar
• Morieri ML, Lamacchia O, Manzato E, Giaccari A, Avogaro A. Physicians’ misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes. Cardiovasc Diabetol. 2022;21(1):57. doi:10.1186/s12933-022-01495-8
   PubMed Web of Science ®Google Scholar
• Berthold HK, Gouni-Berthold I, Böhm M, Krone W, Bestehorn KP. Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovasc Diabetol. 2009;8(1):1–12. doi:10.1186/1475-2840-8-25
   PubMedGoogle Scholar
• Pauff BR, Jiroutek MR, Holland MA, Sutton BS. Statin prescribing patterns: an analysis of data from patients with diabetes in the national hospital ambulatory medical care survey outpatient department and national ambulatory medical care survey databases, 2005–2010. Clin. Ther. 2015;37(6):1329–1339. doi:10.1016/j.clinthera.2015.03.020
   PubMed Web of Science ®Google Scholar
• Karmali KN, Lee J-Y, Brown T, Persell SD. Predictors of cholesterol treatment discussions and statin prescribing for primary cardiovascular disease prevention in community health centers. Preventive Med. 2016;88:176–181. doi:10.1016/j.ypmed.2016.04.011
   PubMed Web of Science ®Google Scholar
• Han Y-M, Lee Y-J, Jang Y-N, et al. Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPARδ-AMPK-PGC-1α Pathway in Dyslipidemic Conditions. Biomed Res. Int. 2020;2020:1–17. doi:10.1155/2020/7806860
   Web of Science ®Google Scholar
• Frisbee JC, Goodwill AG, Stapleton PA, Frisbee SJ, d’Audiffret AC. Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation. Physiol Genom. 2010;42(3):331–341. doi:10.1152/physiolgenomics.00090.2010
   PubMed Web of Science ®Google Scholar
• Simpson RJ, Tunceli K, Ramey DR, et al. Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting. J Clin Lipidol. 2013;7(5):399–407. doi:10.1016/j.jacl.2013.06.002
   PubMed Web of Science ®Google Scholar
• Iskandar MF, Nurmainah N, Susanti R. The risk of atherosclerotic cardiovascular disease among hyperlipidaemia patients and appropriateness of statin therapy. Pharmacol Clin Pharm Res. 2018;3(1). doi:10.15416/pcpr.v3i1.16452
   Google Scholar
• Tawakol A, Fayad ZA, Mogg R, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol. 2013;62(10):909–917. doi:10.1016/j.jacc.2013.04.066
   PubMed Web of Science ®Google Scholar
• Ting RZ, Yang X, Yu LW, et al. Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovasc Diabetol. 2010;9(1):1–9. doi:10.1186/1475-2840-9-77
   PubMedGoogle Scholar
• Ahmed F, Lin J, Ahmed T, Siddiqui D, Nguyen J, Sarpong D. Health disparities: statin prescribing patterns among patients with diabetes in a family medicine clinic. Health Equity. 2022;6(1):291–297. doi:10.1089/heq.2021.0144
   PubMedGoogle Scholar
• Alwhaibi M, Alkofide H. Potentially inappropriate medications use among older adults with dyslipidaemia. J Clin Med. 2023;12(12):4063. doi:10.3390/jcm12124063
   PubMed Web of Science ®Google Scholar
• Kalinić D, Škrbić R, Vulić D, et al. Eleven-year trends in lipid-modifying medicines utilisation and expenditure in a low-income country: a study from the republic of Srpska, Bosnia and Herzegovina. Clinicoecon Outcomes Res. 2023;15:513–523. doi:10.2147/CEOR.S410711
   PubMed Web of Science ®Google Scholar